CompanyGraph
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
600513 · SSE · China
lhpharma.comFinancials as of FY2024–FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.40%Below 5Y avg (1.20%)
Annual Rate
CNY 0.07Paid annual
Payout Ratio
57.7%Sustainable
Last Ex-Dividend
Jul 8, 2026
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2024, balance sheet FY2025, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
4.98BCNY740.76M · vs all stocks (USD)
Revenue (TTM)
2.89BCNY430.48M · vs all stocks (USD)
Profit Margin
-3.97%Beta
-0.2180xvs all stocks
52-Week Change
-29.06%vs all stocks
Market Capitalization
4.98BCNY740.76M · vs all stocks (USD)
Enterprise Value
6.96BCNY1.03B · vs all stocks (USD)
Price to Sales (TTM)
1.80xPrice to Book (MRQ)
4.07xEnterprise to Revenue
2.40xEnterprise to EBITDA
73.87xGross Margin
26.52%Profit Margin
-3.97%Operating Margin
2.43%Return on Assets (TTM)
-0.19%Return on Equity (TTM)
-6.00%Revenue (TTM)
2.89BCNY430.48M · vs all stocks (USD)
Revenue per Share (TTM)
9.73CNYUpdated Aug 20, 2026Quarterly Revenue Growth
29.10%Gross Profit (TTM)
887.29MCNY131.95M · vs all stocks (USD)
EBITDA (TTM)
194.28MCNY28.89M · vs all stocks (USD)
Net Income (TTM)
-114.97MCNY-17.10M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-72.10%Operating Cash Flow (TTM)
-40.33MCNY-6.00M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-195.92MCNY-29.13M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0700CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.40%vs all stocks
5-Year Average Dividend Yield
1.20%vs all stocks
Payout Ratio
57.69%Revenue
2.16BCNYFY2024 · Dec 31, 2024Cost of Goods Sold
1.09BCNYFY2024 · Dec 31, 2024Gross Profit
1.07BCNYFY2024 · Dec 31, 2024Operating Income
143.39MCNY21.32M · vs all stocks (USD)
Pre-tax Income
130.43MCNYFY2024 · Dec 31, 2024Income Tax Expense
24.01MCNYFY2024 · Dec 31, 2024Net Income
106.41MCNYFY2024 · Dec 31, 2024EBIT
155.38MCNYFY2024 · Dec 31, 2024EBITDA (Income Statement)
194.28MCNYFY2024 · Dec 31, 2024Research & Development
154.59MCNYFY2024 · Dec 31, 2024Selling, General & Administrative
638.30MCNYFY2024 · Dec 31, 2024Other Operating Expenses
19.74MCNYFY2024 · Dec 31, 2024Non-operating Interest Income
1.16MCNYFY2024 · Dec 31, 2024Non-operating Interest Expense
24.95MCNYFY2024 · Dec 31, 2024EPS (Basic)
0.2900CNYFY2024 · Dec 31, 2024EPS (Diluted)
0.2900CNYFY2024 · Dec 31, 2024Basic Shares Outstanding
290.21MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
290.21MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
106.41MCNYFY2024 · Dec 31, 2024Minority Interests (P&L)
-22.25MCNYFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00CNYFY2024 · Dec 31, 2024Operating Cash Flow
-60.71MCNYFY2024 · Dec 31, 2024Free Cash Flow
-245.55MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
186.69MCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
106.41MCNYFY2024 · Dec 31, 2024Other Non-cash Items
25.74MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-60.14MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-132.74MCNYFY2024 · Dec 31, 2024Capital Expenditures
-184.84MCNYFY2024 · Dec 31, 2024Purchase of Investments
-22.00MCNYFY2024 · Dec 31, 2024Sale of Investments
22.01MCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-184.83MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
847.98MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-673.49MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-50.57MCNYFY2024 · Dec 31, 2024Other Financing Charges
-10.22MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
113.71MCNYFY2024 · Dec 31, 2024Shares Outstanding
285.46MSharesUpdated Aug 20, 2026Float Shares
167.82MSharesUpdated Aug 20, 2026% Held by Insiders
43.70%vs all stocks
% Held by Institutions
0.43%vs all stocks
Total Cash (MRQ)
265.50MCNY39.48M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9300CNYUpdated Aug 20, 2026Total Debt (MRQ)
1.61BCNY239.34M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9536xCurrent Ratio (MRQ)
0.9360xBook Value per Share (MRQ)
4.48CNYUpdated Aug 20, 2026Cash Equivalents
71.18MCNYFY2025 · Dec 31, 202552-Week Low
13.67CNYUpdated Aug 20, 202652-Week High
32.27CNYUpdated Aug 20, 202652-Week Change
-29.06%vs all stocks
Beta
-0.2180xvs all stocks
50-Day MA
16.28CNYUpdated Aug 20, 2026200-Day MA
19.51CNYUpdated Aug 20, 2026Avg 10-Day Volume
28.75MSharesUpdated Aug 20, 2026Avg 30-Day Volume
29.27MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.4000CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bright Minds Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated